ArticleJAC-antimicrobial resistance2025
Safety and efficacy of continuous cefazolin infusion via peripheral intravenous catheter (PIVC) for outpatient therapy: a brief report.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cefazolin elastomeric infusers are commonly used in outpatient settings with peripherally inserted central catheters (PICCs) or mid-line catheters to treat various infections. However, data on the safety of cefazolin elastomeric infusers administered via a peripheral IV catheter (PIVC) are limited. Objectives: To assess the safety and complications of outpatient cefazolin elastomeric infusers via PIVC. Methods: A retrospective case series study was conducted, reviewing patients treated with cefazolin elastomeric infuser via PIVC between January 2018 and December 2022 in our institution. The primary outcomes assessed were PIVC-related complications using visual infusion phlebitis (VIP) score, including catheter-related bacteraemia and readmissions within 30 days. Results: A total of 415 patients aged ≥18 years were treated with cefazolin elastomeric infuser through PIVC during the 5 year study period. On average, each patient required two PIVCs during outpatient treatment, amounting to 870 PIVCs in total. Of these, 85% ( Conclusions: Outpatient cefazolin elastomeric infusers administered via PIVC were well tolerated and safe.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.